Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 3 | 2020 | 145 | 0.750 |
Why?
|
| Phenytoin | 2 | 2020 | 71 | 0.710 |
Why?
|
| Deep Brain Stimulation | 8 | 2021 | 348 | 0.670 |
Why?
|
| Anticonvulsants | 3 | 2020 | 431 | 0.650 |
Why?
|
| Valproic Acid | 2 | 2020 | 263 | 0.650 |
Why?
|
| Globus Pallidus | 3 | 2021 | 71 | 0.420 |
Why?
|
| Dystonic Disorders | 3 | 2020 | 81 | 0.390 |
Why?
|
| Dystonia | 3 | 2018 | 163 | 0.330 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2022 | 11 | 0.210 |
Why?
|
| Lesch-Nyhan Syndrome | 1 | 2021 | 5 | 0.200 |
Why?
|
| Sports | 1 | 2022 | 80 | 0.200 |
Why?
|
| Double-Blind Method | 5 | 2020 | 2588 | 0.190 |
Why?
|
| Emergency Medicine | 1 | 2022 | 134 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 230 | 0.180 |
Why?
|
| Vitreous Detachment | 1 | 2019 | 12 | 0.170 |
Why?
|
| Fibrinolysin | 1 | 2019 | 33 | 0.170 |
Why?
|
| Visual Field Tests | 1 | 2019 | 50 | 0.170 |
Why?
|
| Retinal Perforations | 1 | 2019 | 31 | 0.170 |
Why?
|
| Visual Fields | 1 | 2019 | 142 | 0.160 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 461 | 0.150 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 20 | 0.150 |
Why?
|
| Child, Preschool | 10 | 2021 | 16273 | 0.150 |
Why?
|
| Cerebellar Ataxia | 1 | 2016 | 72 | 0.140 |
Why?
|
| Adolescent | 13 | 2022 | 31252 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 306 | 0.130 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.130 |
Why?
|
| Efferent Pathways | 1 | 2014 | 9 | 0.120 |
Why?
|
| Visual Acuity | 1 | 2019 | 873 | 0.120 |
Why?
|
| Diazepam | 1 | 2014 | 39 | 0.120 |
Why?
|
| Lorazepam | 1 | 2014 | 40 | 0.120 |
Why?
|
| Child | 11 | 2022 | 29154 | 0.120 |
Why?
|
| Disclosure | 1 | 2014 | 181 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 1271 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 543 | 0.110 |
Why?
|
| Informed Consent | 1 | 2014 | 419 | 0.100 |
Why?
|
| Exome | 1 | 2016 | 1239 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2022 | 1375 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 621 | 0.090 |
Why?
|
| Neuronavigation | 1 | 2009 | 47 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 255 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2483 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2019 | 170 | 0.080 |
Why?
|
| Age Distribution | 1 | 2020 | 698 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 162 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 264 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2019 | 587 | 0.080 |
Why?
|
| Hypotension | 1 | 2019 | 210 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 4938 | 0.070 |
Why?
|
| Male | 14 | 2021 | 123000 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2009 | 232 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.070 |
Why?
|
| Adult | 10 | 2020 | 77950 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 2594 | 0.070 |
Why?
|
| Female | 14 | 2021 | 141928 | 0.070 |
Why?
|
| Pediatrics | 1 | 2014 | 1141 | 0.070 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 183 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2021 | 32848 | 0.060 |
Why?
|
| Humans | 16 | 2022 | 261506 | 0.060 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 35 | 0.050 |
Why?
|
| Infant | 3 | 2020 | 13310 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 7702 | 0.050 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 49 | 0.050 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 58 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 83 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.050 |
Why?
|
| Middle Aged | 6 | 2020 | 86204 | 0.050 |
Why?
|
| Cell Separation | 1 | 2022 | 612 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 245 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 194 | 0.040 |
Why?
|
| Students | 1 | 2022 | 324 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2019 | 60 | 0.040 |
Why?
|
| Macula Lutea | 1 | 2019 | 47 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2019 | 123 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 141 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2022 | 499 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 460 | 0.040 |
Why?
|
| Peroxisomal Multifunctional Protein-2 | 1 | 2016 | 3 | 0.040 |
Why?
|
| Aged | 5 | 2020 | 70117 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1005 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 29902 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2022 | 3033 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 1529 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2020 | 1152 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2014 | 27 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 430 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 827 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1148 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 501 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 75 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 1183 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 256 | 0.030 |
Why?
|
| Time Factors | 2 | 2019 | 12926 | 0.030 |
Why?
|
| Differential Threshold | 1 | 2011 | 14 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 1073 | 0.030 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 627 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 75 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 226 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2011 | 147 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 234 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1265 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 264 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 429 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 6682 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 6295 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 172 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 304 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 183 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2009 | 298 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 445 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 301 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 806 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 37905 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1945 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 4758 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 925 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 4821 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8223 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6100 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 34495 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 15179 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 4892 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4320 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 59536 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 4113 | 0.010 |
Why?
|